Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5890756 | Bone | 2012 | 6 Pages |
Abstract
⺠Risedronate significantly increases lumbar spine BMD from baseline after 4 years of treatment. ⺠Patients switching from placebo to 2 years of risedronate treatment show a significant increase in lumbar spine BMD from baseline. ⺠Few new vertebral and clinical fractures occurred during this open-label extension. ⺠There were no significant differences in BTMs between the two groups at months 36 and 48. ⺠Safety results continued to show that risedronate was well-tolerated in men with osteoporosis.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Steven Boonen, Roman S. Lorenc, Dietrich Wenderoth, Karen J. Stoner, Rachelle Eusebio, Eric S. Orwoll,